Avacta Group PLC aims to develop more valuable/licensable assets

Dr. Alistair Smith, Avacta Group PLC says the company is focused on two ways that would generate value for shareholders – Taking assets through into the clinical phases and to develop more novel assets which would be regarded as valuable and licensable by the Pharma companies.
Smith also updates Tip TV viewers about “excellent” results from the latest study of its Affimer technology and the significant growth in the number of partners worldwide in order to exploit the therapeutic and diagnostic potential of Affimer technology.
Watch the full segment for more info on the company’s future plans and what investors can expect in the rest of 2017.
Get the latest videos in your inbox
Subscribe to our daily newsletter
We respect your privacy.

Leave a Comment

Your email address will not be published. Required fields are marked *